Evidence map›Paper›PMID 35839283›Full record

ArticleCancer science2022

Reticulocalbin3: A Ca

Rui Cai, Ping Wang, Xin Zhao, Xiansheng Lu, Ruxia Deng, Xiaoyu Wang, Chang Hong, Jie Lin

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Reticulocalbin3: A CaCancer science · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rui CaiDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ping WangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xin ZhaoDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiansheng LuDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ruxia DengDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoyu WangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chang HongDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jie LinDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-5952-2319
Key Laboratory of Guangdong Province · CN

Funding

Guangzhou Science and Technology Project 202102080076National Natural Science Foundation of China 81672441National Natural Science Foundation of China 82173298Natural Science Foundation of Guangdong Province 2016A030313580Natural Science Foundation of Guangdong Province 2017A030313607Natural Science Foundation of Guangdong Province 2022A1515012390
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent cancers worldwide. There is a critical need to identify new mechanisms that contribute to ESCC progression. Reticulocalbin3 (RCN3) is mainly located in the endoplasmic reticulum and Ca

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2Cell Line, TumorCell MovementCisplatinGene Expression Regulation, NeoplasticHomeostasisHumansInositol 1,4,5-Trisphosphate ReceptorsMatrix Metalloproteinase 2Matrix Metalloproteinase 9PrognosisReactive Oxygen SpeciesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2CisplatinInositol 1,4,5-Trisphosphate ReceptorsMatrix Metalloproteinase 2Matrix Metalloproteinase 9Reactive Oxygen SpeciesCa2+ homeostasisesophageal squamous cell carcinomametastasisplatinum resistanceRCN3

Identifiers

PMID35839283
PMCPMC9530876
OpenAlexW4285490630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.